{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:49:57Z","timestamp":1791352197167,"version":"4.3.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Whether the total gonadotropin (Gn) dose used for controlled ovarian stimulation is independently associated with live birth and embryo quality remains controversial, largely because the dose is individualized according to patient prognosis, which generates confounding by indication. We examined this association within homogeneous levels of ovarian response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort study analyzed 3,711 fresh autologous embryo transfer cycles (female age \u226435 years, follicular-phase long protocol, January 2016 to June 2025); cycles with trigger-day progesterone \u22651.5 ng\/mL were excluded because fresh transfer was canceled per center policy. Cycles were stratified by oocyte yield into poor (&amp;lt;10, n=1,346), normal (10\u201315, n=1,582), and high (&amp;gt;15, n=783) response. The exposure was the total Gn dose. The primary outcome was the fresh embryo transfer live birth rate; secondary outcomes included clinical pregnancy, early miscarriage, and morphological embryo-quality indicators. We modeled dose\u2013response relationships with restricted cubic splines (RCS), compared dose quartiles within strata using sequentially adjusted logistic regression, controlled the false discovery rate (FDR) by the Benjamini\u2013Hochberg method, and prespecified five sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the overall cohort, the total Gn dose showed neither a linear (P=0.871) nor a nonlinear (P=0.701) association with live birth. Compared with the lowest dose quartile (Q1), fully adjusted odds ratios for Q2, Q3, and Q4 were 1.18 (95% CI: 0.90\u20131.55), 1.08 (0.78\u20131.49), and 1.34 (0.92\u20131.95), and no stratum showed a significant association. In the normal-response stratum, the highest quartile was associated with reduced live birth in the crude model (OR=0.70, P=0.036), but the association attenuated and disappeared with sequential adjustment (aOR=1.08, P=0.757), which quantitatively illustrates how confounding by indication arises and how it can be corrected. No secondary outcome remained significant after FDR correction (minimum q=0.137), and all sensitivity analyses agreed with the main analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Within the same level of ovarian response, the total Gn dose was not significantly associated with fresh embryo transfer live birth or morphological embryo quality. Within the dose range studied (700\u20138,025 IU; interquartile range 1,650\u20132,725 IU), escalating the Gn dose to improve embryo quality or live birth lacks evidential support, and moderate dose increases in patients with reduced ovarian sensitivity showed no signal of harm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1970297","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:51:48Z","timestamp":1791348708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Total gonadotropin dose is not associated with live birth or embryo quality in fresh cycles at equivalent levels of ovarian response: a retrospective cohort study stratified by ovarian response"],"prefix":"10.3389","volume":"17","author":[{"given":"Keng","family":"Feng","sequence":"first","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwen","family":"Wei","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Lei","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derong","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi","family":"Luo","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhu","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Procurement Office, Yulin Maternal and Child Health Hospital","place":["Yulin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1210\/er.2005-0015","article-title":"The science behind 25 years of ovarian stimulation for in vitro fertilization","volume":"27","author":"Macklon","year":"2006","journal-title":"Endocr Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1210\/er.18.1.71","article-title":"Manipulation of human ovarian function: physiological concepts and clinical consequences","volume":"18","author":"Fauser","year":"1997","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil Steril"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antim\u00fcllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertil Steril"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2012.03412.x","article-title":"Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles","volume":"119","author":"La Marca","year":"2012","journal-title":"BJOG"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.fertnstert.2015.07.1151","article-title":"Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles","volume":"104","author":"Baker","year":"2015","journal-title":"Fertil Steril"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41598-024-51991-y","article-title":"Nonlinear relationship between gonadotropin total dose applied and live birth rates in non-PCOS patients: a retrospective cohort study","volume":"14","author":"Xu","year":"2024","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40001-024-01768-w","article-title":"Effects of total gonadotropin dose on embryo quality and clinical outcomes with AMH stratification in IVF cycles: a retrospective analysis of 12,588 patients","volume":"29","author":"Shen","year":"2024","journal-title":"Eur J Med Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2019.05.007","article-title":"The different impact of stimulation duration on oocyte maturation and pregnancy outcome in fresh cycles with GnRH antagonist protocol in poor responders and normal responders","volume":"58","author":"Yang","year":"2019","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00181","article-title":"Individualization of FSH doses in assisted reproduction: facts and fiction","volume":"10","author":"Broekmans","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil Steril"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dev316","article-title":"Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos","volume":"31","author":"Drakopoulos","year":"2016","journal-title":"Hum Reprod"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/des389","article-title":"High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol","volume":"28","author":"Fatemi","year":"2013","journal-title":"Hum Reprod"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.104.032003","article-title":"Follicle-stimulating hormone affects metaphase I chromosome alignment and increases aneuploidy in mouse oocytes matured in vitro","volume":"72","author":"Roberts","year":"2005","journal-title":"Biol Reprod"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/del484","article-title":"Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial","volume":"22","author":"Baart","year":"2007","journal-title":"Hum Reprod"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex299","article-title":"High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer","volume":"32","author":"Barash","year":"2017","journal-title":"Hum Reprod"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-017-0909-3","article-title":"The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response","volume":"34","author":"Sekhon","year":"2017","journal-title":"J Assist Reprod Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa028","article-title":"No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12,298 trophectoderm biopsies","volume":"35","author":"Irani","year":"2020","journal-title":"Hum Reprod"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-024-03183-w","article-title":"Total gonadotropin dose did not affect euploid blastocyst rates: an analysis of more than 19,000 oocytes","volume":"41","author":"Shuai","year":"2024","journal-title":"J Assist Reprod Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.05.050","article-title":"Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders","volume":"96","author":"Shapiro","year":"2011","journal-title":"Fertil Steril"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2015.01.045","article-title":"Freeze-all policy: fresh vs. frozen-thawed embryo transfer","volume":"103","author":"Roque","year":"2015","journal-title":"Fertil Steril"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2010.02545.x","article-title":"A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count","volume":"117","author":"Jayaprakasan","year":"2010","journal-title":"BJOG"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex318","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: The predicted poor responder","volume":"32","author":"Van Tilborg","year":"2017","journal-title":"Hum Reprod"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex319","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 2: The predicted hyper responder","volume":"32","author":"Oudshoorn","year":"2017","journal-title":"Hum Reprod"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012693.pub2","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","volume":"2","author":"Lensen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der037","article-title":"The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting","volume":"26","year":"2011","journal-title":"Hum Reprod"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(00)00518-5","article-title":"Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer","volume":"73","author":"Gardner","year":"2000","journal-title":"Fertil Steril"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of \u2018poor response\u2019 to ovarian stimulation for in vitro fertilization: the Bologna criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Hum Reprod"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.12688\/f1000research.10382.1","article-title":"The novel POSEIDON stratification of \u2018low prognosis patients in assisted reproductive technology\u2019 and its proposed marker of successful outcome","volume":"5","author":"Humaidan","year":"2016","journal-title":"F1000Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2016.02.005","article-title":"A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept","volume":"105","author":"Alviggi","year":"2016","journal-title":"Fertil Steril"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2013.06.049","article-title":"Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem","volume":"100","author":"Huber","year":"2013","journal-title":"Fertil Steril"},{"key":"B35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.rbmo.2017.06.015","article-title":"The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators","volume":"35","year":"2017","journal-title":"Reprod BioMed Online"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7326\/m16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwy201","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0006","article-title":"Ovarian aging: mechanisms and clinical consequences","volume":"30","author":"Broekmans","year":"2009","journal-title":"Endocr Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/humrep\/15.1.29","article-title":"Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation","volume":"15","author":"Out","year":"2000","journal-title":"Hum Reprod"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez184","article-title":"Individualized ovarian stimulation in IVF\/ICSI treatment: it is time to stop using high FSH doses in predicted low responders","volume":"35","author":"Leijdekkers","year":"2020","journal-title":"Hum Reprod"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/8.5.413","article-title":"Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction","volume":"8","author":"Simoni","year":"2002","journal-title":"Hum Reprod Update"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.05.055","article-title":"Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization","volume":"89","author":"Pal","year":"2008","journal-title":"Fertil Steril"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt014","article-title":"Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles","volume":"19","author":"Venetis","year":"2013","journal-title":"Hum Reprod Update"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum Reprod"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2016.1199018","article-title":"An upper limit of gonadotropin dose in patients undergoing ART should be advocated","volume":"32","author":"Friedler","year":"2016","journal-title":"Gynecol Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1970297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:04Z","timestamp":1791348724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1970297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":45,"alternative-id":["10.3389\/fendo.2026.1970297"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1970297","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1970297"}}